Fremman Capital (“Fremman”) is pleased to announce the acquisition of a majority stake in HT Médica, with the goal of accompanying the Luna family, the current majority shareholder, in its next stage of growth.
HT Médica is one of the leading operators in Spain in the provision of radiology and diagnostic imaging services. The company has 20 diagnostic imaging centres and 2 laboratory centres throughout Andalucía, Castilla La Mancha, Asturias and Madrid. Its services portfolio includes MRI, CT, ultrasound, RX and laboratory services. HT Médica has an excellent reputation for quality and a solid track record of clinical leadership.
The diagnostic imaging market is expected to grow significantly over the coming years, fuelled by factors like the rising emphasis on preventive medicine, increased awareness, and the importance of early diagnosis. Technological advances also play a crucial role, allowing for the use of more advanced modalities.
Dr. Antonio Luna, CEO and Medical Director of HT Médica, said: “We are very excited about this next stage of growth together with Fremman as our new partner. In partnering with Fremman we see an incredible opportunity to continue with and expand our reach and further elevate the quality standards of diagnostic imaging across Spain, while preserving our vision of providing the best medical services to our patients, referrals and public/private customers. Fremman has an extensive and solid track record in expanding and implementing technology into the operations. We are excited about the prospects that this partnership holds for the future.”
Ricardo de Serdio, Founding Partner and CEO of Fremman, added: “This partnership aligns perfectly with our strategic vision, we are committed to unlocking new avenues of growth while fostering innovation and maintaining the highest standards of service. Fremman is fully committed to help the management team drive future value creation and consolidate HT Médica’s leading position in the. coming years. The strength and medical quality of the management team will ensure continued growth and success.”
HT Médica is Fremman’s sixth platform investment, having been signed just a few months after announcing the final closing of its debut fund, raising over €600 million, and its first platform exit (Palex Medical). Since inception, the firm has completed five platform investments: Bollo Natural Fruit (Spain), VPS (Netherlands), Medinet (UK), Palex Medical (Spain) and Kids Planet (UK) and more than 50 add-on investments.
AZ Capital (M&A), KPMG (Financial) and GA_P (Legal, Tax and Labour) have been acting as advisers to the Sellers, while Natixis Partners (M&A), Deloitte (Financial, Legal, Tax and Labour), Pérez-Llorca (Legal) and LEK (Commercial) have been advisers to Fremman in the transaction.
About HT Médica
HT Médica is one of the leading operators in Spain in the provision of radiology and diagnostic imaging
services. The company has 20 diagnostic imaging centres and 2 laboratory centres throughout
Andalucía, Castilla La Mancha, Asturias and Madrid. Its services portfolio includes MRI, CT, ultrasound,
RX, and laboratory services.
For more information, please visit https://htmedica.com/.
Fremman is a pan-European, mid-market investment firm with offices in London, Luxembourg, Madrid,
Munich and Paris that looks to partner with successful management teams to help transform businesses
from local champions to multinational sustainable leaders. Its senior Partners have a long history
working together, with over 100 years of combined investment experience. Fremman’s goal is to build
better, more sustainable businesses that have a positive impact on society.
For more information, please visit https://fremman.com/.